Medpace Holdings, Inc. (MEDP) Stock

About Medpace Holdings, Inc.

Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.

Medpace Holdings, Inc. is led by CEO August James Troendle, employs 6,200 people, headquartered in Cincinnati, US, publicly traded since 2016.

Medpace Holdings, Inc. (MEDP) stock trades at $576.49 with a market capitalization of $16.09B. The stock is valued at a price-to-earnings (P/E) ratio of 26.43, price-to-book of 20.04, price-to-sales of 4.48. Over the past 52 weeks the stock has ranged between $305.69 and $628.92, and currently trades 8.3% below its 52-week high.

On profitability, Medpace Holdings, Inc. generates a return on equity (ROE) of 77.25% — well above the market average, a sign of a high-quality business, return on capital employed of 116.56%, an operating margin of 21.02%, a net profit margin of 17.19%.

In its most recent fiscal year, Medpace Holdings, Inc. reported annual revenue of $2.5B, net profit of $451.0M, revenue has compounded at 22.3% a year over the last five years, profit at 25.5% a year. Profit growing faster than revenue points to expanding margins.

The balance sheet shows a debt-to-equity ratio of 0.24 — a conservative balance sheet with little leverage risk, a current ratio of 0.74, total assets of $2.0B, $497.0M in cash and equivalents.

MEDP has an average daily trading volume of 345,701 shares, a beta of 1.18.

Official website: www.medpace.com